Loading…
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vanc...
Saved in:
| Published in: | Journal of antimicrobial chemotherapy 1999-04, Vol.43 (4), p.569-573 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643 |
| container_end_page | 573 |
| container_issue | 4 |
| container_start_page | 569 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 43 |
| creator | VON EIFF, C PETERS, G |
| description | The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vancomycin and teicoplanin, using an agar dilution method. A total of 245 clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains, were tested. The new agents tested exhibited wide-spectrum antistaphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. In contrast to the quinolones, the in-vitro activities of quinupristin/dalfopristin, linezolid and the glycopeptides remained almost unchanged, irrespective of the resistance phenotype for methicillin. A number of isolates with elevated quinolone MICs were observed. |
| doi_str_mv | 10.1093/jac/43.4.569 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69791779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17252641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643</originalsourceid><addsrcrecordid>eNqFkUFr3DAQhUVpabZpbz0XUUpO8e7IkiXrWJamLQRySc5iLMutFlvaSPaSFPrfq7ALKb30NDzmm2HmPULeM1gz0HyzQ7sRfC3WjdQvyIoJCVUNmr0kK-DQVEo0_Iy8yXkHALKR7WtyxoA3wFu9Ir-3cdpjwtkfHPWhOvg5RYq2aD97l2kc6BQf_DDGB7Q-XNLSP-CzvF98WPbJ59mHTY_jEE-CYujp6IP7FUffU_yBPuSZ5hn3Px_HaKO1_i15NeCY3btTPSd3V19ut9-q65uv37efrysrVDtX2HeOiZp3DnUthdRNB4gKe6YUdN3QWtFzpWuhu06KwXGndPFBQKt4XSo_JxfHvfsU7xeXZzP5bN04YnBxyUbqMqCU_i_IVN2UC1gBP_4D7uKSQnnC1ExJybiCAl0eIZtizskNpngzYXo0DMxTeKaEZwQ3wpTwCv7htHPpJtf_BR_TKsCnE4DZFqsTBuvzM6eEBq74H4VFpGc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217661370</pqid></control><display><type>article</type><title>Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>VON EIFF, C ; PETERS, G</creator><creatorcontrib>VON EIFF, C ; PETERS, G</creatorcontrib><description>The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vancomycin and teicoplanin, using an agar dilution method. A total of 245 clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains, were tested. The new agents tested exhibited wide-spectrum antistaphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. In contrast to the quinolones, the in-vitro activities of quinupristin/dalfopristin, linezolid and the glycopeptides remained almost unchanged, irrespective of the resistance phenotype for methicillin. A number of isolates with elevated quinolone MICs were observed.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/43.4.569</identifier><identifier>PMID: 10350389</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acetamides - pharmacology ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Aza Compounds ; Biological and medical sciences ; Fluoroquinolones ; Humans ; Linezolid ; Medical sciences ; Methicillin Resistance ; Microbial Sensitivity Tests ; Moxifloxacin ; Naphthyridines - pharmacology ; Oxazoles - pharmacology ; Oxazolidinones ; Pharmacology. Drug treatments ; Quinolines ; Staphylococcal Infections - microbiology ; Staphylococcus ; Staphylococcus - drug effects ; Staphylococcus - isolation & purification ; Virginiamycin - pharmacology</subject><ispartof>Journal of antimicrobial chemotherapy, 1999-04, Vol.43 (4), p.569-573</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Apr 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643</citedby><cites>FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1749037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10350389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VON EIFF, C</creatorcontrib><creatorcontrib>PETERS, G</creatorcontrib><title>Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vancomycin and teicoplanin, using an agar dilution method. A total of 245 clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains, were tested. The new agents tested exhibited wide-spectrum antistaphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. In contrast to the quinolones, the in-vitro activities of quinupristin/dalfopristin, linezolid and the glycopeptides remained almost unchanged, irrespective of the resistance phenotype for methicillin. A number of isolates with elevated quinolone MICs were observed.</description><subject>Acetamides - pharmacology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Aza Compounds</subject><subject>Biological and medical sciences</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>Linezolid</subject><subject>Medical sciences</subject><subject>Methicillin Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Moxifloxacin</subject><subject>Naphthyridines - pharmacology</subject><subject>Oxazoles - pharmacology</subject><subject>Oxazolidinones</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcus</subject><subject>Staphylococcus - drug effects</subject><subject>Staphylococcus - isolation & purification</subject><subject>Virginiamycin - pharmacology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkUFr3DAQhUVpabZpbz0XUUpO8e7IkiXrWJamLQRySc5iLMutFlvaSPaSFPrfq7ALKb30NDzmm2HmPULeM1gz0HyzQ7sRfC3WjdQvyIoJCVUNmr0kK-DQVEo0_Iy8yXkHALKR7WtyxoA3wFu9Ir-3cdpjwtkfHPWhOvg5RYq2aD97l2kc6BQf_DDGB7Q-XNLSP-CzvF98WPbJ59mHTY_jEE-CYujp6IP7FUffU_yBPuSZ5hn3Px_HaKO1_i15NeCY3btTPSd3V19ut9-q65uv37efrysrVDtX2HeOiZp3DnUthdRNB4gKe6YUdN3QWtFzpWuhu06KwXGndPFBQKt4XSo_JxfHvfsU7xeXZzP5bN04YnBxyUbqMqCU_i_IVN2UC1gBP_4D7uKSQnnC1ExJybiCAl0eIZtizskNpngzYXo0DMxTeKaEZwQ3wpTwCv7htHPpJtf_BR_TKsCnE4DZFqsTBuvzM6eEBq74H4VFpGc</recordid><startdate>19990401</startdate><enddate>19990401</enddate><creator>VON EIFF, C</creator><creator>PETERS, G</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19990401</creationdate><title>Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci</title><author>VON EIFF, C ; PETERS, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Acetamides - pharmacology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Aza Compounds</topic><topic>Biological and medical sciences</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>Linezolid</topic><topic>Medical sciences</topic><topic>Methicillin Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Moxifloxacin</topic><topic>Naphthyridines - pharmacology</topic><topic>Oxazoles - pharmacology</topic><topic>Oxazolidinones</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcus</topic><topic>Staphylococcus - drug effects</topic><topic>Staphylococcus - isolation & purification</topic><topic>Virginiamycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VON EIFF, C</creatorcontrib><creatorcontrib>PETERS, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VON EIFF, C</au><au>PETERS, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1999-04-01</date><risdate>1999</risdate><volume>43</volume><issue>4</issue><spage>569</spage><epage>573</epage><pages>569-573</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vancomycin and teicoplanin, using an agar dilution method. A total of 245 clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains, were tested. The new agents tested exhibited wide-spectrum antistaphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. In contrast to the quinolones, the in-vitro activities of quinupristin/dalfopristin, linezolid and the glycopeptides remained almost unchanged, irrespective of the resistance phenotype for methicillin. A number of isolates with elevated quinolone MICs were observed.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10350389</pmid><doi>10.1093/jac/43.4.569</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 1999-04, Vol.43 (4), p.569-573 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69791779 |
| source | Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list) |
| subjects | Acetamides - pharmacology Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Aza Compounds Biological and medical sciences Fluoroquinolones Humans Linezolid Medical sciences Methicillin Resistance Microbial Sensitivity Tests Moxifloxacin Naphthyridines - pharmacology Oxazoles - pharmacology Oxazolidinones Pharmacology. Drug treatments Quinolines Staphylococcal Infections - microbiology Staphylococcus Staphylococcus - drug effects Staphylococcus - isolation & purification Virginiamycin - pharmacology |
| title | Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A32%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20in-vitro%20activities%20of%20moxifloxacin,%20trovafloxacin,%20quinupristin/dalfopristin%20and%20linezolid%20against%20staphylococci&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=VON%20EIFF,%20C&rft.date=1999-04-01&rft.volume=43&rft.issue=4&rft.spage=569&rft.epage=573&rft.pages=569-573&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/43.4.569&rft_dat=%3Cproquest_cross%3E17252641%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-adbe1423bea9264695b0aa7ad1770bbf8c4d379249bb64fe3e791464087324643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217661370&rft_id=info:pmid/10350389&rfr_iscdi=true |